74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Regeneron Pharmaceuticals Inc
Closed
Sector Healthcare
699.52 0.48
Overview
Share price change
24h
Min
698.04
Max
703.58
Income | -423M 918M |
|---|---|
Sales | 69M 3.8B |
P/E Sector Avg | 17.888 73.394 |
EPS | 12.07 |
Profit margin | 24.219 |
Employees | 15,106 |
EBITDA | -534M 1.1B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +36.88 upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | 329M 75B |
|---|---|
Previous open | 699.04 |
Previous close | 699.52 |
News Sentiment
By Acuity
77%
23%
360 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Regeneron Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Regeneron Pharmaceuticals Inc Forecast
Price Target
By TipRanks
36.88% upside
12 Months Forecast
Average 958.6 USD 36.88%
High 1,182 USD
Low 575 USD
Based on 20 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
360 / 393 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
